• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lite Strategy Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    2/12/26 5:10:57 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LITS alert in real time by email
    8-K
    false000126210400012621042026-02-122026-02-12

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): February 12, 2026

     

     

    Lite Strategy, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41827

    51-0407811

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    9920 Pacific Heights Blvd.,

    Suite 150

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 858 369-7100

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.00000002 par value

     

    LITS

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 5.02 Departure of Directors; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On February 12, 2026, at the fiscal 2026 Annual Meeting of Stockholders (the Annual Meeting) of Lite Strategy, Inc. (the Company), the Company’s stockholders approved the Company’s 2026 Omnibus Equity Compensation Plan (the 2026 Equity Plan). The 2026 Equity Plan had been approved by the Company’s Board of Directors on December 17, 2025, subject to the approval of the stockholders, and became effective upon approval by the stockholders on February 12, 2026. The 2026 Equity Plan is attached hereto as Exhibit 10.1.

    Approval of the 2026 Equity Plan by the stockholders satisfied the contingency in the previously-disclosed grant under the 2026 Equity Plan to Mr. File of options (the “Replacement Options”) to purchase 455,000 shares of the Company’s common stock, $0.00000002 par value. The terms of the grant of the Replacement Options are described in the Company’s Current Report on Form 8-K/A filed with the Securities and Exchange Commission on November 20, 2025, and are incorporated herein by reference.

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    At the Annual Meeting held on February 12, 2026, there were represented, by proxy, 19,437,130 shares of the Company’s common stock, par value $0.00000002 per share (Common Stock), out of a total number of 36,785,397 shares of Common Stock outstanding and entitled to vote at the Annual Meeting. The Company’s stockholders voted on the following four proposals at the Annual Meeting, casting their votes as described below.

    Proposal 1. – Election of Director.

    The following individuals, who were named as nominees in the Company’s definitive proxy statement relating to the Annual Meeting, were elected by the Company’s stockholders by a plurality of votes cast to serve until the expiration of their terms in fiscal year 2029 and until their successor is elected and qualified. Information on the vote relating to the directors standing for election is set forth below:

     

    Nominee

    For

    Withheld

    Broker Non-Votes

    Mr. Justin J. File

    7,554,160

     

    4,779,999

     

    7,102,971

    Mr. Joshua Riezman

    7,558,908

     

    4,775,251

     

    7,102,971

     

    Proposal 2. – Advisory Vote on Executive Compensation.

    Proposal 2 was to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement. The proposal was approved.

    For

    Against

    Abstain

    Broker Non-Votes

    6,006,580

     

    5,538,689

     

    788,890

     

    7,102,971

    Proposal 3. – Ratification of Appointment of CBIZ CPAs.

    Proposal 3 was to ratify the appointment of CBIZ CPAs, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending June 30, 2026. The proposal was approved.

    For

    Against

    Abstain

    18,939,953

    430,917

     

    66,260


    Proposal 4. – Approval of Lite Strategy, Inc's 2026 Omnibus Equity Compensation Plan.

    Proposal 4 was to approve the Company's 2026 Omnibus Equity Compensation Plan. The proposal was approved.

    For

    Against

    Abstain

    Broker Non-Votes

    6,630,087

     

    5,697,274

     

    6,798

     

    7,102,971

     

    Item 9.01 Financial Statements and Exhibits.

    Exhibit Number

    Exhibit Title

    10.1

    Lite Strategy, Inc. 2026 Stock Omnibus Equity Compensation Plan (incorporated by reference to Annex A to the Company’s Definitive Proxy Statement, filed with the Securities and Exchange Commission on December 30, 2025).


    104

    Cover Page Interactive Data File (formatted as inline XBRL)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    LITE STRATEGY, INC.

     

     

     

     

    Date:

    February 12, 2026

    By:

    /s/ Justin J. File

     

     

     

    Justin J. File
    Chief Executive Officer, Chief Financial Officer and Secretary

     


    Get the next $LITS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LITS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LITS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Flynn James P bought $97,699 worth of shares (70,000 units at $1.40), increasing direct ownership by 233% to 100,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P bought $22,777 worth of shares (12,100 units at $1.88), increasing direct ownership by 68% to 30,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    11/20/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lite Strategy Reports Fiscal 2026 Second Quarter Results

    SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or the "Company"), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced financial results for the fiscal 2026 second quarter ended December 31, 2025. During the second quarter, the Company successfully launched its strategic initiative to transform its LTC holdings into a productive reserve asset, utilizing covered call options while also implementing a $25 million stock repurchase program. "The second quarter marked a pivotal shift in our evolution. We moved from simply accumulating LTC to launching our first active capital market operat

    2/17/26 8:50:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations

    SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS") today reported results for its first quarter ended September 30, 2025, and highlighted recent corporate events related to the Company's digital asset treasury strategy as well as its pharmaceutical operations. "Our first quarter was incredibly successful for LITS. We launched our digital treasury strategy, positioning ourselves as the leading public holder of LTC, and updated our corporate profile to reinforce our new focus," Board Member Charlie Lee said. "We recently celebrated Litecoin's 14th anniversary and its unblemished track record of reliability and uptime. LITS provides inv

    11/17/25 9:00:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations

    SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS") today announced its Board of Directors has authorized a program to repurchase shares of the Company's Common Stock, par value $0.00000002 per share (the "Common Stock"), up to an aggregate amount of $25 million. The share repurchase program is effective immediately, and provides for shares to be repurchased in the open market or through negotiated transactions. "Our top priority is to enhance stockholder value," said Board Member Joshua Riezman, U.S. Chief Strategy Officer at GSR, which is advising the Company on its treasury strategy, "and the share repurchase program is one of th

    10/29/25 9:00:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    SEC Filings

    View All

    Lite Strategy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lite Strategy, Inc. (0001262104) (Filer)

    2/17/26 8:50:24 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lite Strategy Inc.

    10-Q - Lite Strategy, Inc. (0001262104) (Filer)

    2/17/26 8:45:49 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Lite Strategy, Inc. (0001262104) (Filer)

    2/12/26 5:10:57 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO, CFO and Secretary File Justin J.

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    2/12/26 5:44:48 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Schornstein Alexander sold $946,137 worth of shares (690,611 units at $1.37), decreasing direct ownership by 16% to 3,674,862 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:15:14 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P bought $97,699 worth of shares (70,000 units at $1.40), increasing direct ownership by 233% to 100,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    12/22/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care